News
Antiviral Research The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro OPEN ACCESS https://doi.org/10.1016/j.antiviral.2020.104787 “Highlights: Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro. A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture. Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing. Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines. Abstract Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. ...”
Quick Links
-
Please see MONOGRAPH in Veterinaria Italiana
“One Health – One Medicine”: linking human, animal and environmental health
Read More -
History of the One Health Initiative team and website (April 2006 through September 2015) and the One Health Initiative website since October 1, 2008 … revised to June 2020 and again to date February 2021
Read More -
Vaccines for zoonoses: a One Health paradigm
SciTech Europa Quarterly (March 2018) – Issue 26
Read More -
Pan European Networks SciTech Europa Quarterly
SciTech Europa Vaccines for zoonoses: a one Health paradigm – Pages 227-229 (Read PDF) “One of the One Health Initiative team’s co-founders and leaders is an internationally-recognized eminent physician…
Read More Read PDF